Retreatment with CTL019/CTL119 in Patients with Late Relapse of B-Cell Lymphomas
Enrolling By Invitation
18-99 years
All
Phase
1
12 participants needed
1 Location
Brief description of study
The primary objective of this study is to evaluate the safety of retreatment of patients with CTL019/CTL119 therapy who have experienced late relapse of lymphoma.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Lymphomas
-
Age: Between 18 Years - 99 Years
-
Gender: All
Diffuse Large B-Cell Lymphoma or Follicular lymphoma, previously identified as CD19+ Previously treated with CTL019/CTL119, with historical manufactured product available at Penn for reinfusion
Updated on
22 Aug 2024.
Study ID: 834286
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
